Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tambiciclib |
| Synonyms | |
| Therapy Description |
Tambiciclib inhibits CDK9, resulting in decreased activation of RNA Pol II and transcription of anti-apoptotic proteins, potentially leading to decreased tumor growth (J Clin Oncol 43, 2025 (suppl 16; abstr 3121, NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tambiciclib | GFH-009|GFH 009|GFH009|SLS009|SLS-009|SLS 009 | CDK9 Inhibitor 21 | Tambiciclib inhibits CDK9, resulting in decreased activation of RNA Pol II and transcription of anti-apoptotic proteins, potentially leading to decreased tumor growth (J Clin Oncol 43, 2025 (suppl 16; abstr 3121, NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04588922 | Phase Ib/II | Azacitidine + Venetoclax Tambiciclib Azacitidine + Tambiciclib + Venetoclax | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | Recruiting | USA | 1 |